HOTH•benzinga•
Hoth Therapeutics Announces Preclinical Data For HT-KIT, With IND Filing Expected In Early 2026; Says 'HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga